About: Characterization of Neutralizing Profiles in HIV-1 Infected Patients from whom the HJ16, HGN194 and HK20 mAbs were Obtained

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Characterization of Neutralizing Profiles in HIV-1 Infected Patients from whom the HJ16, HGN194 and HK20 mAbs were Obtained Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Characterization of Neutralizing Profiles in HIV-1 Infected Patients from whom the HJ16, HGN194 and HK20 mAbs were Obtained
Creator	Corti, Davide Lanzavecchia, Antonio Heyndrickx, Leo Vanham, Guido Davis, David Heyndrickx, Liesbeth Janssens, Wouter Vereecken, Katleen Willems, Betty Balla-Jhagjhoorsingh, Sunita Ng, Lisa Poh, Fong Seaman, Michael
Source	PMC
abstract	Several new human monoclonal antibodies (mAbs) with a neutralizing potential across different subtypes have recently been described. Three mAbs, HJ16, HGN194 and HK20, were obtained from patients within the HIV-1 cohort of the Institute of Tropical Medicine (ITM). Our aim was to generate immunization antibodies equivalent to those seen in plasma. Here, we describe the selection and characterization of patient plasma and their mAbs, using a range of neutralization assays, including several peripheral blood mononuclear cell (PBMC) based assays and replicating primary viruses as well as cell line based assays and pseudoviruses (PV). The principal criterion for selection of patient plasma was the activity in an ‘extended incubation phase’ PBMC assay. Neutralizing Abs, derived from their memory B cells, were then selected by ELISA with envelope proteins as solid phase. MAbs were subsequently tested in a high-throughput HOS-PV assay to assess functional neutralization. The present study indicates that the strong profiles in the patients' plasma were not solely due to antibodies represented by the newly isolated mAbs. Although results from the various assays were divergent, they by and large indicate that neutralizing Abs to other epitopes of the HIV-1 envelope are present in the plasma and synergy between Abs may be important. Thus, the spectrum of the obtained mAbs does not cover the range of cross-reactivity seen in plasma in these carefully selected patients irrespective of which neutralization assay is used. Nevertheless, these mAbs are relevant for immunogen discovery because they bind to the recombinant glycoproteins to which the immune response needs to be targeted in vivo. Our observations illustrate the remaining challenges required for successful immunogen design and development.
has issue date	2011-10-10(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0025488
bibo:pmid	22016769
has license	cc-by
sha1sum (hex)	b85bcfe513307afbac6c3bd5866dc0c0aecd28a5
schema:url	https://doi.org/10.1371/journal.pone.0025488
resource representing a document's title	Characterization of Neutralizing Profiles in HIV-1 Infected Patients from whom the HJ16, HGN194 and HK20 mAbs were Obtained
has PubMed Central identifier	PMC3189917
has PubMed identifier	22016769
schema:publication	PLoS One
resource representing a document's body	covid:b85bcfe513307afbac6c3bd5866dc0c0aecd28a5#body_text
is schema:about of	named entity 'phase' named entity 'spectrum' named entity 'assays' named entity 'Our' named entity 'strong' named entity 'high-throughput' named entity 'PATIENTS' named entity 'TESTED' named entity 'MONOCLONAL ANTIBODIES' named entity 'SEEN' named entity 'OBSERVATIONS' named entity 'VARIOUS' named entity 'HIV-1' named entity 'INFECTED' named entity 'IMMUNE RESPONSE' named entity 'CRITERION' named entity 'ACROSS' named entity 'REQUIRED' named entity 'DIFFERENT' named entity 'SPECTRUM' named entity 'RANGE' named entity 'BASED' named entity 'IMMUNOGEN' named entity 'FUNCTIONAL' named entity 'MAY BE' named entity 'SYNERGY' named entity 'DERIVED' named entity 'GLYCOPROTEINS' named entity 'EPITOPES' named entity 'PATIENTS' named entity 'NEWLY' named entity 'ISOLATED' named entity 'DESCRIBE' named entity 'OBTAINED' named entity 'CROSS' named entity 'DUE TO' named entity 'THROUGHPUT' named entity 'DOES NOT' named entity 'CHARACTERIZATION' named entity 'DISCOVERY' named entity 'THEIR' named entity 'ACTIVITY' named entity 'REACTIVITY' named entity 'ASSESS' named entity 'TARGETED' named entity 'STRONG' named entity 'SUCCESSFUL' named entity 'INCUBATION' named entity 'PLASMA' named entity 'OBTAINED' named entity 'COHORT' named entity 'DESCRIBED' named entity 'ABS' named entity 'HERE' named entity 'REPLICATING' named entity 'BIND' named entity 'HAVE' named entity 'IMPORTANT' named entity 'ANTIBODIES' named entity 'CELL LINE' named entity 'THESE' named entity 'SUBTYPES' named entity 'HUMAN' named entity 'RELEVANT' named entity 'REMAINING' named entity 'ENVELOPE' named entity 'SOLID PHASE' named entity 'OUR' named entity 'PRIMARY'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software